The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Open accessAbstract
With the identification of activating mutations in BRAF across a wide variety of malignancies, substantial effort was placed in designing safe and effective therapeutic strategies to target BRAF. These efforts have led to the development and regulatory approval of three BRAF inhibitors as well as five combinations of a BRAF inhibitor plus an additional agent(s) to manage cancer such as melanoma, non–small cell lung cancer, anaplastic thyroid cancer, and colorectal cancer. To date, each regimen is effective only in patients with tumors harboring BRAFV600 mutations and the duration of benefit is often short-lived. Further limitations preventing optimal management of BRAF-mutant malignancies are that treatments of non-V600 BRAF mutations have been less profound and combination therapy is likely necessary to overcome resistance mechanisms, but multi-drug regimens are often too toxic. With the emergence of a deeper understanding of how BRAF mutations signal through the RAS/MAPK pathway, newer RAF inhibitors are being developed that may be more effective and potentially safer and more rational combination therapies are being tested in the clinic. In this review, we identify the mechanics of RAF signaling through the RAS/MAPK pathway, present existing data on single-agent and combination RAF targeting efforts, describe emerging combinations, summarize the toxicity of the various agents in clinical testing, and speculate as to where the field may be headed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,763
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Research works printed but not linked: 2
- Corcoran, 2020, Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients [abstract]
- Janku, 2020, Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor [abstract], S2—3
Cited by
Sorted by citations
Items 101–145 of 145
Targeting BRAF in cancers – from molecular diagnostics to personalized therapy
Pyc, Z., Rygiel, R., Michałowska, D., Ekiert, M., & Łaczmańska, I. (2025) · Biotechnologia · doi:10.5114/bta/213740 · Cited by 1
Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics
Ananda, H., Sahana, S. R., Murthy, S. R., Kunnath, A. N., Prashant, A., Kaifi, J. T., Kiran, P. K., & Suvilesh, K. N. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1828450 · Cited by 1
Pathways and targeting avenues of BRAF in non-small cell lung cancer
Имянитов, Е. Н., Mitiushkina, N. V., Kuligina, E. S., Tiurin, V. I., & Venina, A. R. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2374742 · Cited by 2
Wu, J., Cheng, H.-X., Lan, Q., Xu, H.-Y., Zeng, Y.-J., Wei, L., & Chu, Z. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.100152 · Cited by 1
Schulz, W. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-16286-2_23
[Clinical significance of multigene assay in papillary thyroid carcinoma].
Shi, Y., Qian, K., Guo, K., Liu, J., & Wang, Z. (2023) · PubMed Central · doi:10.13201/j.issn.2096-7993.2023.05.011
Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?
Corno, C., Beretta, G. L., & Perego, P. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.006
FOXP3 (rs 3761548) and BRAF (V600E ) gene polymorphism among Egyptians with hepatocellular carcinoma
Elmougy, R., Safan, M., Ali, R., Denewer, A. T., & El-Saeed, R. A. (2024) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2023.2300209
Kasi, P. M., Lee, J., Pasquina, L. W., Decker, B. J., Borre, P. V., Pavlick, D. C., Allen, J. M., Parachoniak, C. A., Quintanilha, J. C. F., Graf, R. P., et al. (2024) · doi:10.1158/1078-0432.c.7077717.v1
Schulz, W. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-42806-7_23
Koçdor, M. A., Kaya, Y., Ateş, H., BILDIK, E., & Koçdor, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4134744/v1
The phenomenon of the BRAF and TERTp mutational duet in melanoma and other cancers
Rusinek, D., Pfeifer, A., Zajkowicz, A., Tęcza, K., Pamuła‐Piłat, J., Czarnecka, A. M., & Oczko‐Wojciechowska, M. (2024) · Nowotwory Journal of Oncology · doi:10.5603/njo.103026
Scarlato, E., Casalino, S., Mendo, L., Sordo, A., Vita, V. D., Lorenzo, E. S., Quinzii, A., Zecchetto, C., Butturini, G., & Melisi, D. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100179
The Rho/MRTF-pirin axis: a promising target for overcoming melanoma drug resistance
Chen, X., Zhang, J., Zhang, B., & Li, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1571933
Sun, X. (2025) · American Journal of Cancer Research · doi:10.62347/mvnl2093
Wang, X., Zhao, Z., Liu, L., Cheng, J., & Ba, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.01.673435
Vázquez, S. J., Patsis, C., Mitstorfer, M., Grimm, M., Butthof, L., Wendler-Link, L., Böse, L., Wiethoff, H., Hofmann, I., Breuhahn, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.17.675062
Liu, J., Liang, X., Wang, K., Zhang, C., Li, C., Zhao, L., Kuang, Y., Wang, M., Liu, J., Zhou, L., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02773-6
Xiao, Y., Wang, J., Zhao, X., Xu, J., Zhao, H., Guo, Z., Zhao, J., Zhang, Y., Wang, R., & Zhang, Y. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1172
Li, W., Zhao, C., Li, W., Gong, Y., Ma, K., Lu, Y., Liu, X., Zhang, L., & Guo, F. (2024) · Figshare · doi:10.6084/m9.figshare.26628619
Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S., Halbach, S., & Brummer, T. (2023) · Figshare · doi:10.6084/m9.figshare.23519961
Li, W., Zhao, C., Li, W., Gong, Y., Ma, K., Lu, Y., Liu, X., Zhang, L., & Guo, F. (2024) · Figshare · doi:10.6084/m9.figshare.26628610
Li, W., Zhao, C., Li, W., Gong, Y., Ma, K., Lu, Y., Liu, X., Zhang, L., & Guo, F. (2024) · Figshare · doi:10.6084/m9.figshare.26628622
Li, W., Zhao, C., Li, W., Gong, Y., Ma, K., Lu, Y., Liu, X., Zhang, L., & Guo, F. (2024) · Figshare · doi:10.6084/m9.figshare.26628613
Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S., Halbach, S., & Brummer, T. (2023) · Figshare · doi:10.6084/m9.figshare.23519955
Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S., Halbach, S., & Brummer, T. (2023) · Figshare · doi:10.6084/m9.figshare.23519964
Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S., Halbach, S., & Brummer, T. (2023) · Figshare · doi:10.6084/m9.figshare.23519958
Jarvis, A. F., Bhat, M. Y., Maujean, T., Abreu, A. L., Toy, K., Burslem, G. M., & Brady, D. C. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00231
Targeted therapies and small molecule inhibitors
Kumar, A., Sharma, V., Behl, T., Arora, S., Sharma, N., & Singh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00014-5
Nagai, S., Suzuki, R., Yamakawa, G., Fukuda, A., Seno, H., & Tanaka, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.07.710277
Abbouda, A., Barone, V., Manni, P., Cutrupi, F., Appolloni, A., & Appolloni, R. (2026) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2026.2642359
Zhang, W., Gao, Y., Zeng, S., Li, J., Wang, S., Huang, Y., & Dou, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-44229-6
Next-generation sequencing: overview and application to systemic cancer and brain tumors
Newton, H. B., & Pinho, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00067-x
Nizard, S., Chen, Y., Serasinghe, M. N., Fernández‐Rodríguez, R., Shultz, K. D., Khatun, J., Mendoza, A., Gelles, J. D., Henao-Martinez, J. F., Abraham‐Enachescu, I., et al. (2026) · Antibodies · doi:10.3390/antib15020038
Lefkovits, Y. R., McLean, L. S., Middleton, M. R., & Thomas, D. M. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03079-y
de Almeida, K. Y., Imasa, M. S. B., Voon, P. J., Hoo, H. F. S., Chen, T. W., Yusak, S., Ramachandran, R., Bakar, N. A., Chen, M., Yatabe, Y., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00907
Ramachandran, S., Berglind, A., Hébert, J., Jung, Y., Murch, M., Perez, S., Barkovich, M. J., Mirchia, K., Chang, E. F., Canoll, P., et al. (2026) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlag055
Astolfi, M., Masin, M., Anfuso, A., Malagu', C., Anania, G., Benedusi, M., Valacchi, G., & Rispoli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156647
Cruz, E., Magaña-Curiel, G., Aguirre-Guillén, R. L., & Rodríguez-Machuca, V. U. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.08.004
ANXA1 ‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2
Feng, J., Huang, X.-P., Zhang, M., Huang, W., Lu, S., Xiao, Z., Xie, Z., & Yi, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71310
Bharti, J., Gogu, P., Sarwan, D. N., Pathak, M. K., Gupta, P. S., Dwivedi, A. R., & Pathak, P. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118379
Vázquez, S. J., Berthel, A., Patsis, C., Mitstorfer, M., Grimm, M., Butthof, L., Wendler-Link, L., Böse, L., Wiethoff, H., Hofmann, I., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77465-5
Orive-Ramos, A., Gaire, B., Adamopoulos, C., Baars, B., Desaunay, M., Kou, Z., Matenoglou, E., Coma, S., Gutiérrez, N., Mohammed, K., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1596 · Cited by 1
Self-citationLiberko, M. (2026) · Onkologie · doi:10.36290/xon.2026.040
Abdelaziz, R. A. I., Ghannam, I. A. Y., Allam, H. A., Kerdawy, A. M. E., Allam, R. M., Abo-Elfadl, M. T., & Abbas, S. E.-S. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110709
Metadata
- Authors
- Poulikakos, P. I., Sullivan, R. J., & Yaeger, R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Sullivan, Ryan J.
- Yaeger, Rona
- Venue
- Clinical Cancer Research
- Published
- 2022-04-29
- Volume
- 28
- Issue
- 21
- Pages
- 4618-4628
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC9616966
- OpenAlex
- W4225136170
- Cited by
- 145
- References
- 125
- Citations by year
- 2026: 29 · 2025: 41 · 2024: 41 · 2023: 31 · 2022: 3
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54 CA224068, P30 CA008748, R01 C233736, R01 CA204314, R01 CA240362, R01CA238229, R01 CA193970, R01 CA229851, UM1 CA186709)
- Irma T. Hirschl Trust
- Melanoma Research Alliance
- Melanoma Research Foundation
- Breast Cancer Alliance
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF, BRAF inhibitors, BRAF V600 mutation, RAS/MAPK pathway, Raf signaling, combination therapy, melanoma, non-small cell lung cancer, anaplastic thyroid carcinoma, colorectal cancer, drug resistance, drug toxicity, targeted cancer therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
